BioNTech’s Dual Burden: Advancing Oncology Trials While Navigating Berlin’s Vaccine Stockpile Fallou
BioNTech launches Phase 1/2 trial for Pumitamig in renal cancer while navigating 7.6M unused vaccine doses, a 25%…
Browsing Tag